{"filing":{"accession_number":"0001104659-26-083880","cik":"0000744218","ticker":"CLDX","company_name":"Celldex Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"tm2620527d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/744218/000110465926083880/tm2620527d1_8k.htm"},"events":[{"id":18129,"run_id":16284,"accession_number":"0001104659-26-083880","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Sam Martin, Senior Vice President and Chief Financial Officer, notified the Company of his plans to retire effective March 31, 2027. The principal disclosed action is the departure of a named executive officer (CFO) from the Company, with a clear effective date and transition plan. This is a material event affecting investor assessment of the registrant's leadership and financial management continuity.","company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16846,"accession_number":"0001104659-26-083880","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Sam Martin, Senior Vice President and Chief Financial Officer, notified the Company of his plans to retire effective March 31, 2027. The principal disclosed action is the departure of a named executive officer (CFO) from the Company, with a clear effective date and transition plan. This is a material event affecting investor assessment of the registrant's leadership and financial management continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:09:37.244846+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16846,"accession_number":"0001104659-26-083880","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Sam Martin, Senior Vice President and Chief Financial Officer, notified the Company of his plans to retire effective March 31, 2027. The principal disclosed action is the departure of a named executive officer (CFO) from the Company, with a clear effective date and transition plan. This is a material event affecting investor assessment of the registrant's leadership and financial management continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:09:37.244846+00:00","company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","filing_date":"2026-07-15"}]}